<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>DSpace Collection:</title>
  <link rel="alternate" href="http://hdl.handle.net/10362/5240" />
  <subtitle />
  <id>http://hdl.handle.net/10362/5240</id>
  <updated>2013-06-02T23:01:47Z</updated>
  <dc:date>2013-06-02T23:01:47Z</dc:date>
  <entry>
    <title>Downstream processing development of enveloped viruses for clinical applications: innovative tools for rational process optimization</title>
    <link rel="alternate" href="http://hdl.handle.net/10362/5247" />
    <author>
      <name>Vicente, Tiago</name>
    </author>
    <id>http://hdl.handle.net/10362/5247</id>
    <updated>2012-06-08T18:23:25Z</updated>
    <published>2010-09-01T00:00:00Z</published>
    <summary type="text">Title: Downstream processing development of enveloped viruses for clinical applications: innovative tools for rational process optimization
Authors: Vicente, Tiago
Abstract: Viral vectors and virus-like particles hold a tremendous potential in various clinical applications in the areas of gene therapy and/or vaccination, drawing the attention of biotechnology and pharmaceutical companies. The majority of these products are manufactured in animal cell cultures, inherently making the process costly. A great deal of effort is taking place to generate optimized biological and engineering strategies to find scalable&#xD;
and cost-effective processes, easily transferable to cGMP facilities. However, the implementation of robust downstream processes generating this type of biopharmaceuticals in the amounts required for pre-clinical and clinical trials is still lacking and lagging. By including a labile lipid membrane layer harboring glycoproteins (often critical for infection)&#xD;
over the viral capsid, enveloped viruses bring extra challenges in terms of their bioprocessing particularly downstream. The work developed during this thesis aimed at improving the state-of-the-art purification processes for these types of viral particles. The rationale was to integrate process understanding with product characterization, still scarce in such biological systems.(...)
Description: Dissertation presented to obtain a Ph.D. degree in Engineering and Technology&#xD;
Sciences, Biotechnology at the Instituto de Tecnologia Química e Biológica,&#xD;
Universidade Nova de Lisboa</summary>
    <dc:date>2010-09-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Production optimization of rotavirus-like particles: a system biology approach</title>
    <link rel="alternate" href="http://hdl.handle.net/10362/5246" />
    <author>
      <name>Roldão, António Manuel Missionário</name>
    </author>
    <id>http://hdl.handle.net/10362/5246</id>
    <updated>2011-02-22T17:06:02Z</updated>
    <published>2010-06-01T00:00:00Z</published>
    <summary type="text">Title: Production optimization of rotavirus-like particles: a system biology approach
Authors: Roldão, António Manuel Missionário
Abstract: Rotavirus-like particles (RLPs), a vaccine candidate against rotavirus&#xD;
disease, were produced by infecting Spodoptera frugiperda Sf-9 cells with&#xD;
genetically engineered recombinant baculoviruses. RLPs are spherically&#xD;
shaped particles composed by three viral proteins (vp) of rotavirus, vp2,&#xD;
vp6 and vp7, arranged in a triple layered structure.&#xD;
A diversity of protein structures, other than the correctly assembled RLP,&#xD;
are observed at the end of a typical production run suggesting that the&#xD;
protein assembly process is rather inefficient. Contaminants such as&#xD;
trimers of vp6 and vp7, vp6 tube-like structures, single-layered vp2&#xD;
particles, double layered particles of vp2 and vp6 or RLPs lacking one or&#xD;
more subunits represent almost 88% of the total mass of proteins&#xD;
expressed. Thus, optimal control of protein expression concomitant with&#xD;
efficient particle assembly are critical factors for economical RLP&#xD;
production in the baculovirus/insect cells system.
Description: Dissertation presented to obtain a Ph.D. degree in Engineering and Technology Sciences, Systems Biology at the Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa</summary>
    <dc:date>2010-06-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Gammaretroviral and lentiviral vectors for gene therapy: stability and inactivation mechanisms</title>
    <link rel="alternate" href="http://hdl.handle.net/10362/5241" />
    <author>
      <name>Carmo, Marlene</name>
    </author>
    <id>http://hdl.handle.net/10362/5241</id>
    <updated>2011-02-22T16:27:52Z</updated>
    <published>2009-01-01T00:00:00Z</published>
    <summary type="text">Title: Gammaretroviral and lentiviral vectors for gene therapy: stability and inactivation mechanisms
Authors: Carmo, Marlene
Description: Dissertation presented to obtain a Ph.D degree in Engineering and Technology&#xD;
Sciences, Gene Therapy at the Instituto de Tecnologia Quimica e Biológica,&#xD;
Universidade Nova de Lisboa</summary>
    <dc:date>2009-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

